New cocktail aims to stall pancreatic cancer after chemo

NCT ID NCT03404960

Completed Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding an immunotherapy drug (ipilimumab or nivolumab) to niraparib, a targeted therapy, can prevent advanced pancreatic cancer from growing. It enrolled 104 adults whose cancer had not worsened after platinum-based chemotherapy. The goal was to see how long the cancer stayed under control and whether the combination was safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: niraparib plus either ipilimumab or nivolumab
What this could lead to: If successful, this combination could offer a new treatment option to keep advanced pancreatic cancer from growing for longer after initial chemotherapy.
What could go wrong: This is an early-phase, completed trial with only 104 participants, so results may not apply broadly. Combining drugs also raises the risk of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

University of Pennsylvania, Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.